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Abstract
The 10B isotope has been almost exclusively used in the neutron-capture radiation therapy
(NCT) of cancer for decades. We have identified two other nuclides suitable for the radiotherapy,
which have ca.10 times larger cross section of absorption for neutrons and emit heavy charged
particles. This would provide several key advantages for potential NCT, such as the possibility to
use either a lower nuclide concentration in the target tissues, or a lower neutron irradiation flux.
By detecting the characteristic γ radiation from the spontaneous decay of the radionuclides, one
can image and control their accumulation. These advantages could be critical for the revival of the
NCT as a safer, more efficient and more widely used cancer therapy.
∗ communications may be sent to igor.bodrenko@dsf.unica.it
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INTRODUCTION
The use of the ionizing radiation in treatment of cancer has a long and successful history
[1], and it is one of the most remarkable examples of direct medical outreach as results of
modern physics. Energetic photons, leptons or heavy charged particles can ionize biological
matter creating lethal damages to living cells through the direct disintegration of important
biomolecules (like DNA or RNA) and by creating chemically active radicals destroying cell’s
biochemistry [2]. The radiation therapy is a valid alternative and a complementary treatment
to the surgery and to the chemotherapy in oncology practices, used in more than 50% of
patients with cancer [3].
One of the issues in the radiation therapy is to deliver the ionization selectively into a
spatially localized region occupied by the tumor, ranging from few millimeters to several
centimeters in size. The surrounding healthy tissues must receive as small radiation damage
as possible to avoid side effects [3]. The ionizing radiation can be delivered from outside
the patient, – a method known as external-beam radiation therapy (EBRT). Heavy charged
particles (protons, accelerated nuclei) have an advantage over leptons and photons due to
relatively small range straggling and to the sharp Bragg peak in the energy loss vs the
path length curve, located in the end of particle’s range in the tissue [4–6]. Therefore, the
radiation damage to the tissues may be localized inside the tumor. The heavy particles,
however, have shorter ranges in matter than light particles and photons at the same kinetic
energy. Therefore, to access tumors deep in the body one needs to accelerate the particles
up to the energies of few hundreds MeV/u, to deliver and to focus the beam onto the target
in human body. This makes the infrastructure for the heavy particle radiation therapy very
complex, expensive, and limited to large medical/research centers, while a much cheaper
gamma-ray radiation therapy has come to many common hospitals [5, 7].
A way to overcome the problem of delivery of fast particles into tumor is to put the ra-
diation source directly into the cancerous tissue. This idea is realized by physically placing
a radioactive nuclide enclosed in a protective capsule or as a wire inside (or next to) the
target tissues (brachytherapy), what often requires surgery [8]. Alternatively, one may use
radioactive nuclides bound into radiopharmaceuticals selectively transported into the target
tissues [9]. The spontaneous decay of a radioisotope nucleus may release up to several tens
of MeV, converted into the kinetic energy of charged product particles and deposited into
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the ionization in the range within less than a millimeter around the decaying nucleus. The
radionuclide therapy, therefore, replaces the problem of kinematic delivery of the ionizing
particle into the target tissue in EBRT with the problem of selective accumulation of ra-
diopharmaceuticals . The radionuclide therapy also brings a new issue – the problematic
temporal control. The timescales of the accumulation and of the excretion of radiopharma-
ceuticals (which are regulated by the metabolism and are difficult to control) should be in
due relation to the lifetime of the isotope, so that to maximize the part of the nuclei decayed
in the tumor and not on their way into or out of the target. It is not possible to initiate and
to stop the therapy on an arbitrary moment. Moreover, many radionuclides as well as their
products are heavy elements, which are known for their toxicity and problematic excretion
[3].
In the neutron capture radiation therapy (NCT) the active isotope undergoes induced
radioactive decay following the capture of a neutron. This method combines the local
energy deposition property of the radionuclide therapy and a good temporal control of the
beam-particle radiation therapy, as the neutron flux may be switched on and off quickly.
The idea was suggested in 1936 [10] and then implemented for the first time in 1954 [11],
by utilizing 10B isotopes and the reaction 10B(n,αγ)7Li. But despite more than 60 years
of research and development, the boron neutron capture therapy (BNCT) is still in the
experimental phase [12–15]. Several issues are cited as the reason of this situation, [16].
First, it is often difficult to identify the boron-containing compounds that can be selectively
accumulated and kept at the necessary concentration in the tumor cells. Second, besides
many successful cases of practical applications, a significant number of side effects due to the
neutron irradiation of healthy tissues was observed. Third, the BNCT requires high enough
neutron flux (1010 to 1012 cm−2s−1) available only on nuclear reactors and on large-scale
accelerator complexes until recently, so that the infrastructure is complex, expensive and
not well suited for systematic massive clinical studies.
Only one other element, gadolinium, mainly 157Gd isotope in the reaction 157Gd(n,γ)158Gd,
has been considered for NCT, though in much lesser extent [17]. Indeed the effect of its
huge thermal neutrons absorption cross section (by more than 60 times larger than that
for 10B) is diminished by the fact that in the most cases the 158Gd∗ excitation energy is
taken away from the targeted tissues by high-energy γ photons, which does not create any
local ionization. On average, only a small part of the excitation energy (less than 1%) is
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radiated in the form of the electrons via the internal conversion and Auger mechanisms,
which is converted into the ionization within 0.1 mm range from the source [18]. As a result,
GdNCT has no obvious benefits over BNCT and still remains in the experimental phase,
mostly focused on the identification of appropriate tumor-selective Gd delivery agents or of
hybrid B-Gd-containing compounds [19].
In the present work, we have identified two new nuclides, 7Be and 22Na, suitable for the
radiation therapy, and suggest to consider them for potential use in the novel NCT.
NUCLIDES PROPERTIES
Both 7Be and 22Na are unstable radionuclides (see Fig.1) and are well-known to physicists.
7Be decays into stable 7Li via the electron capture mechanism with the half-life of 53 days.
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Figure 1. Schematic diagrams of the 7Be (a) and of the 22Na (b) spontaneous decay, the data are
from [20] and [21], respectively.
As the decay rate depends on the electronic density at the nucleus, 7Be has been used in
the studies of the effect of the chemical environment onto the nuclear processes [22–24].
Besides, and even more importantly, 7Be is assumed to play a key role in the lithium yield
of the big bang nucleosynthesis for standard cosmology via the neutron absorption reaction
7Be(n,p)7Li, [25, 26]. 22Na decays mainly by emitting positrons and the γ-radiation into the
stable 22Ne isotope, and have the half-life of 2.6 years. It is important for the nucleosynthesis
problem [27] and also is used in the positron emission tomography (PET).
In Table I, we summarize the neutron capture properties of the two radionuclides and
compare them with the properties of 10B. The neutron capture reactions pass via an inter-
4
Table I. Neutron capture properties [27–29]
nuclide properties
10B(Jpi = 3+) stable 7Be
(
3
2
−
)
53.2 d
−→
7Li 22Na(3+) 2.60 y
−→
22Ne
main reaction channels:
”0”–the ground state of daughter nucleus; ”1” – the first excited state
10B+n → 11B∗ → 7Be+n → 8Be∗ → 22Na+n → 23Na∗ →
(93.3%)7Li1+α1+γ (1.2%)
7Li1+p1+γ (99.15%)
22Ne1+p1+γ
(6.7%) 7Li0+α0 (98.8%)
7Li0+p0 (0.85%)
22Ne0+p0
kinetic energy of heavy particle products in the predominant channel, [MeV]
0.84(7Li1) + 1.47(α1) 0.21(
7Li0) + 1.44(p0) 0.10(
22Ne1) + 2.25(p1)
total neutron capture cross section
σnX
√
En, [kb eV
1/2]
0.6114 7.0 5.0
σnX (En[eV]) [kb]
σnα(0.0253) = 3.844 σnp(0.0253) = 44 σnp(0.0253) = 31
σnα(1.0) = 0.611 σnp(1.0) = 7.0 σnp(1.0) = 5.0
σnα(10) = 0.193 σnp(10) = 2.2 σnp(10) = 1.6
σnα(100) = 0.0611 σnp(100) = 0.7 σnp(100) = 0.5
mediate compound nucleus in an excited state, – 11B, 8Be, or 23Na, correspondingly. The
compound nuclei then decay into the daughter nuclei ( the 7Li in the case of B and Be and
the 22Ne for Na) by emitting a heavy particle – an α-particle for boron and a proton in the
cases of beryllium and sodium. With the probability of 93.3%, the 11B∗ decays into the first
excited state of 7Li emitting the characteristic 478 keV γ-radiation (see, Fig.1a). Also 23Na∗
mainly (99.15%) decays into the first excited state of its daughter nucleus, 22Ne, emitting a
1.275 MeV photon (see, Fig.1b). In contrast, the 8Be∗ decays predominantly (98.8%) into
the ground state of 7Li. The cross section for the 10B(n,αγ)7Li reaction is well determined
(see recent update in [28]). It follows Bethe’s ∝ 1/v law with the accuracy better than 5%
for the neutron incident energies En < 100 keV, so that σnα
√
En = 0.6114 kb eV
1/2. The
cross section of the 7Be(n,p)7Li follows the ∝ 1/v law for a much smaller neutron kinetic
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energy range, En < 100 eV, [26]. Moreover, there is inconsistency (of more than 20%)
between the values of σnα obtained by different research groups. Thus, for the thermal neu-
trons (En = 0.0253 eV) the neutron capture cross section varies from 38.4 ± 0.8 kb [30] to
52.3± 5.2 kb [26]. This discrepancy is still under debates [29]. We have adopted the latest
result, [29], so that σnα
√
En = 7.0 kb eV
1/2 in the above mentioned neutron energy range.
The 22Na(n,pγ)22Ne reaction also follows the ∝ 1/v law till the neutron energies, En < 100
eV, so that σnα
√
En = 5.0 kb eV
1/2 [27].
It is interesting to note that, besides 7Be and 22Na, there are no other reasonably stable
nuclides that have the capture cross section for the thermal and the epithermal neutrons
larger than that for 10B and emit a high LET radiation suitable for NCT, [28]. There are
very strong neutron absorbers like 135Xe and 113Cd, but via the (n, γ) reaction, i.e. emitting
γ-radiation not suitable for the NCT.
NEUTRON CAPTURE ENERGY DEPOSITION
For more direct comparison of the BNCT with potential BeNCT and NaNCT, we estimate
the energy deposition after neutron capture in water, see Table II, considering only the
predominant reaction channels. The γ-radiation emitting in the predominant channels for
BNCT and NaNCT (Table I) is a low linear energy transfer (LET) radiation, i.e. it has
low probability to produce ionization in the vicinity of the decaying nuclide, rather escaping
from the tumor region. A part of the decay energy may be transformed into the electronic
excitation of the daughter nucleus via different mechanisms (e.g., the internal conversion,
the coulomb excitation by the emitting charged particles, the shake-off due to the instant
change of the nucleus charge and of its momentum) and can be released in the forms of
Auger electrons and photons. But for the light elements considered here (Be, B and Na),
the energy released in this form and its biological effects may probably be neglected for
the NCT, in contract with the heavy elements like Gd, where the internal conversion is
important [18]. Thus, only the kinetic energy, Et, transferred to charged heavy particles
(high LET radiation) is useful for the NCT and are reported in the top of Table II. The
ranges of the protons and of the α-particles in water are taken from [31], while those for the
Li and Ne ions are from [32].
To relate the radiation doses in water to the biological context, we will consider the
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Table II. BNCT (left) vs BeNCT (center) vs NaNCT (right): the energy deposition in water. The
values ”per cell” stand for per mass, Mcell = 2.3 ng; En denotes the neutron kinetic energy.
high LET radiation energy, Et, MeV
2.31 1.65 2.35
ranges [µm] of the high LET radiation
Rα = 8 , RLi = 5 Rp = 44 , RLi = 2 Rp = 92 , RNe < 1
number of reactions per cell (Nr)
required for the dose of 20 Gy
120 170 120
nuclide concentration, c(En) [µg g
−1]
(in parenthesis – the number of nuclides per cell, Ncell(En))
required for the dose of 20 Gy absorbed
during 1 hour exposition to neutron flux of 1010 s−1cm−2
En = 0.0253 eV
6.5 (0.9×109) 0.56 (0.11×109) 1.7 (0.11×109)
En = 1.0 eV
41 (5.7×109) 3.5 (0.69×109) 11 (0.68×109)
En = 10.0 eV
130 (18×109) 11 (2.2×109) 34 (2.1×109)
En = 100.0 eV
410 (57× 109) 35 (6.9× 109) 110 (6.8×109)
typical cell linear dimension, Lcell = 13 µm, and the typical cell mass, Mcell = 2.3 ng, [33].
Also, we will assume Dt = 20 Gy in tumor tissues for a typical dose required for the NCT in
a single run [5, 12]. To compare the nuclides, we use the number of neutron capture reaction
per cell, Nr, required to release locally the absorbed radiation dose Dt, [33]. This quantity
is independent on the neutron capture probability and reflects only the difference (among
the nuclides) in the total energy of high LET radiation following the neutron capture. Only
a part of the nuclides in the cell absorbs neutrons and contribute to the radiation dose,
depending on the neutron flux, Jn, the neutron kinetic energy, En, the absorbtion cross
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section, σn(En) and the time of the irradiation. Therefore, the required number, Ncell, of
nuclides per cell to give the absorbed dose D while exposing for time t to neutron flux Jn is a
more relevant quantity to compare nuclides for the NCT. Alternatively to Ncell, the relative
concentration, c, of the nuclide in the target (in the units of ppm or µg of the nuclide per 1
g of tissue) is often used. Both Ncell and c are shown in Table II for Dt = 20 Gy, t = 1h,
Jn = 10
10 s−1cm−2 and for different neutron kinetic energies.
BENCT AND NANCT: ADVANTAGE AND PERSPECTIVE
Based on the data and the estimates shown in the tables, we can discuss pros and cons
of the potential BeNCT and NaNCT in comparison to the existing BNCT. First, one finds
that the neutron absorption cross section for 7Be is more than 10 times (see, Table I) larger
and for 22Na is more than 8 times larger than that for 10B for En < 100 eV. This principal
advantage of the 7Be is somewhat counterbalanced by a lower (by 30%) released kinetic
energy of the high LET radiation (see, Table II). For 22Na the kinetic energy release is
almost the same as for 10B. In the end, the required number of 7Be nuclides per cell, Ncell
is the same as for 22Na, and it is at least 8 times smaller that that for the boron, at the
same neutron flux and the exposition time. For example, for thermal neutrons, one would
need 0.9× 109 10B nuclei per 2.3 ng of water (typical cell) to obtain 20 Gy of the absorbed
radiation dose after 1 hour of exposition to Jn = 10
10s−1cm−2 neutron flux, while only
1.1 × 108 of 7Be or of 22Na is required. This ratio remains valid till the neutron kinetic
energy of 100 eV. As the requirement of sufficient concentration of the nuclide is one of the
key issues in BNCT [15], the reduction by the factor of 8 in case of 7Be and of 22Na may be
crucial for the success of the NCT. The larger cross section would also make it possible to
bring the required dose to the tumors more deeply buried in the body [33] than for BNCT,
thus increasing the potential applicability of the therapy.
It is worth to note that the main ionizing particles are different for boron and for the new
nuclides (α-particles and protons, respectively), so that the biological effect may be different
at the same total kinetic energy. On one side, the α-particle has a shorter range and, if
the 10B is located close to the cell nucleus, it will release its kinetic energy within several
microns, creating maximum radiation damages directly to the DNA. The proton radiated
by 7Be or 22Na after the neutron capture travels tens of microns and can release its kinetic
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energy to several cells, thus reducing the biological damages to each one. On the other hand,
if the activated nuclide is located in the cell far from the nucleus, the α-particle can stop
before reaching the important organelles and produces only a small radiation damage. The
proton, however, has a higher probability to hit a cell nucleus while crossing several adjacent
cells, and thus might be more efficient. Which of the above contributions dominates in the
biological effect of the NCT will also depends on the mode the nuclide is accumulated inside
the tumor cells. This is one key question for future experimental studies.
Another way to profit from the larger neutron capture cross section for the new nuclides
is to reduce the intensity of neutron flux, again by a factor of 8, while keeping the nuclide
concentration in tumor the same as for 10B. This would give two novel potential benefits
to the BeNCT and the NaNCT. First, the probability of activation of the nuclei in the
healthy tissues will be reduced by 8 times compared to BNCT, thus reducing the adverse
side effects. This should have very serious implications, for example, when treating the
brain glioblastoma and other brain cancers where the tumor is embedded deeply inside the
brain tissue [13, 34]. One needs to apply epithermal neutrons to reach the tumor in the
case. On the other hand, the healthy brain tissue is very sensitive to the radiation damage
coming from epithermal neutrons, so that any significant reduction of the necessary neutron
flux would be very beneficial for the cancer therapy of the brain tumors. Second, a lower
required intensity (108−9s−1cm−2) of the neutron beam would make it possible to use a
smaller scale and cheaper accelerator-based neutron sources [35, 36]. This would make the
NCT economically more efficient and more widely used.
Positrons, from the spontaneous decay of 22Na can be used in the positron emission to-
mography (PET). But also the characteristic γ-radiation (478 keV) from spontaneous decay
of 7Be (see, Fig. 1a) and the γ (1.28 MeV) from the spontaneous decay of 22Na (see, Fig. 1b)
can be utilized very favorably in the standard single photon emission computer tomography
(SPECT) [37] to trace the accumulation of the nuclide before the neutron irradiation. This
is also an important advantage over the BNCT, where the control of the nuclide accumu-
lation is difficult. There, one labels additionally the boron-containing compound with a
radioactive nuclide, e.g., 18F, with subsequent positron emission tomography (PET) [38].
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OPEN PROBLEMS
There are also new challenges on the way of 7Be and 22Na to the successful NCT.
22Na is used for PET and it is already a commercial product. On the 10-1000 ng scale nec-
essary for experimental studies, 7Be may be produced as a byproduct on existing accelerator-
based neutron sources utilizing, e.g., the proton induced spallation reaction on 16O [39]. For
potential industrial-scale application, a dedicated production infrastructure will be neces-
sary. In this respect, the idea (first suggested in [40]) of an accelerator for NCT utilizing the
reverse reaction, 7Li(p,n)7Be, and an intense (10 mA and more) proton beam to produce
neutrons looks especially attractive. Here, the beryllium isotope made during neutron gen-
eration can be further utilized for BeNCT, thus also reducing the cost of radioactive waste
management.
The radiotoxicity problem of these radioactive isotopes is another one. That is, one has to
understand and to minimize the adverse effects of the spontaneous radiation on the patient,
but also on his/her family, the personnel and the environment during the drug production,
administration, excretion, and the radioactive waste management. To assess the effects of
the spontaneous radiation of the 7Be and the 22Na nuclides, we compare them [33] with
the iodine radioisotope, 131I, which emits similar radiation (β and γ), and it is widely used
in the therapy of thyroid cancer [41]. For the radiation therapy, one uses the amount of
131I equivalent to the activity ranging from 0.2 to more than 50 GBq [41]. As 4.6 GBq
corresponds to 1 µg of the nuclide, one can take 1 µg as a typical mass per procedure with
131I. The same mass of 7Be in the target would be necessary to produce 20 Gy per hour in 1 g
of tumor in BeNCT (see, Table II). The external dose rate at the distance of 1 m from the
source, D˙ext, which characterizes the radiation risk for the environment and the personnel, is
2.5 times smaller for 7Be (0.09 mGy/h) than for the typical therapeutic amount of 131I. For
22Na, the necessary mass of the nuclide is 3 µg per 1 g of tumor, and D˙ext = 0.21 mGy/h is
similar to that of 1 µg of 131I. The β component of the internal spontaneous dose is absorbed
locally, within 2 mm from the source. It produces the therapeutic effect in the tumor and
it is harmful when the radionuclide is the healthy tissues. In the case of 131I, the dose rate
is D˙βint = 360 mGy/h for 1 µg of the nuclide; it is 8 times lower for 3 µg of
22Na and it is
absent for 7Be. However, the main therapeutic effect of 22Na and of 7Be comes from the
neutron capture reaction and has the absorbed dose rate of 20 Gy/h, i.e., it is more than 50
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time stronger than for 131I. The γ component of the internal dose is absorbed (by definition)
within the sphere of R = 10 cm from the decaying nuclides and, most probably, outside
the tumor. Therefore, it makes the radiation damage to healthy tissues with the same dose
rate of about D˙γint = 60 mGy/h per 1 µg of
131I or per 3 µg of 22Na; the effect is 2.5 time
smaller for 1 µg of 7Be. Therefore, we conclude that if administered in the same amount as
131I for the thyroid cancer therapy (i.e., in the range of micrograms), the radiation risk of
from spontaneous decay of 7Be and 22Na would be at the same level or smaller then that for
131I. Thus, the nuclides can be managed and administered by following standard security
procedure and technologies for radiopharmacuticals. But simultaneously the therapeutic
effect for the tumor can be much stronger and with better temporal control for NCT than
for the standard radionuclide treatment.
However, the problem, and this is the principal challenged for the future NCT research, is
how to provide the targeting, the accumulation and the pharmacokinetic timescales for 7Be
and 22Na at least at the same level as in the case of 131I therapy for thyroid cancer. In other
words, one needs a pharmaceutical which binds the radionuclide, transport it selectively into
a specific cancerous tissue providing the nuclide concentradion of 1-3 ppm for several hours,
and then is excreted together with the remained non-activated nuclides within several days.
Of the total administered amount of several (maximum, few tens) micrograms of the nuclide
per procedure (the amount is limited by the spontaneous radiation risk), a substantial part
(probably, more than 10%) should pass through the tumor. The above mentioned limitations
of the total amount of nuclide and the required pharmacokinetics would also eliminate the
problem of chemical toxicity of the pure elements, in particular, that for beryllium [42].
Besides, there is the second criterion of the nuclide accumulation selectivity coming from
the requirement to minimize the radiation risk under neutron irradiation – the ratio of the
nuclide concentration in the tumor and in the surrounding healthy tissues must be more
than 3 [16].
The earlier approach employed in BNCT consists of binding the active nuclide into a solu-
ble enough and low-toxic compound administered in large quantities to achieve the desirable
concentration in the target tissue. Two examples of this approach are boronophenylalanine
(BPA) and sodium borocaptate (BSH) [15]. However, the selectivity of accumulation for
these compounds is not sufficient for the radionuclides. For example, one had to administer
around 10 mg of boron per 1 kg of patient’s weight [16] to achieve the necessary concentra-
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tion of the nuclide in tumor. Therefore, only a small part of 10B ends up in tumor, while
almost 1 g of that goes into healthy tissues and should be excreted. Obviously, this ap-
proach does not fit the BeNCT and NaNCT due to the spontaneous radioactivity. Another
method of delivery can be based on recent developments in the nanomedicine [15, 43] and
could be utilized for the new NCT. This modular approach can comprise two or three of
the following steps. One first binds the nuclide in a stable compound, then encapsulates
it into a nanoparticle having sufficient solubility, pharmacokinetics and low toxicity, and
finally functionalizes the nanoparticles to target specific cells. The nanomedicine approach
can potentially provide a very high selectivity, and it is especially suitable for NCT. Here,
there is no need to release the drug in the target tissues as in the case of chemically act-
ing compounds – the ionizing radiation will exit the nanocage anyway. Moreover, it would
be an advantage to keep the non-activated nuclides tightly encapsulated during the whole
procedure to eliminate the radiotoxicity risk and control the excretion. A possible mean to
bind beryllium or sodium in order to protect it from the interaction with aqueous medium
is to encapsulate it into fullerens (or sealed nanotubes). We have shown recently [24, 44],
that the energetic barrier for beryllium to cross the wall of a fulleren is 1-2 eV. Then, a
poorly soluble fulleren can be functionalized or encapsulated (into, e.g. a liposome) to im-
prove the pharmacokinetics, and be further functionalized to target the specific tissue, by
following existing nanomedicine techniques [15, 43]. Otherwise, recent developments in the
beryllium-organic chemistry [45, 46] could provide other options for coordination of beryl-
lium in organic chelators. We are not intended to discuss in details the chemistry issues in
BeNCT and NaNCT here.
CONCLUSION
Instead, we have put forward physical arguments in favor of potential use of 7Be and 22Na
for the neutron capture therapy. We have discussed its advantages vs existing BNCT and
also the limitations and new challenges arising from the radioactivity and the production
issues. The use of new nuclides alone or in combination with traditional 10B and/or 157Gd
would open up a new way in the neutron capture therapy, unexplored before. There no
other reasonably stable nuclides that have the capture cross section for the thermal end
epithermal neutrons larger than that for 10B and emit a high LET radiation suitable for
12
NCT. By combining BeNCT and NaNCT with SPECT (or NaNCT with PET) one would
obtain a real theranostics – simultaneous diagnostics and targeted therapy of cancerous
tissues, – an important ingredient of modern personalized medicine.
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SUPPLEMENTARY MATERIALS
Materials and Methods
a. Typical cell size and mass. The average volumes of human cells range from 30 to
4× 106 µm3, depending on the tissue [47]; the corresponding linear dimensions range from
3 to 160 µm. For the estimates, we will assume the typical cancer cell volume, Vcell =
2300 µm3, and the typical cell linear dimension, Lcell = 13 µm, which corresponds to HeLa
cells often used in cancer in vitro studies [47]. Then, we assume the mass density of the cell,
ρcell = 1 g cm
−3, so that the typical cancer cell’s mass, Mcell = 2.3 ng.
b. Estimation of the absorbed radiation dose under the neutron irradiation. The dose
of hight LET radiation absorbed in a cell reads, D = EtNr/Mcell, where Nr is the number
of the neutron capture reactions happened. Thus, the required Nr to release locally in the
cell the absorbed radiation dose D is, Nr = DMcell/Et. Here, we underline again, we have
assumed that the gamma-radiation after neutron capture has a small probability to interact
and ionize matter within the tumor region (< 10 cm), so that the locally deposed energy
is only that of the charged particles, Et. The corresponding estimates for the BNCT, the
BeNCT and the NaNCT are shown in Table II, assuming D = 20 Gy in tumor tissues for a
typical dose required for the radiation therapy in a single run [5, 12].
The absorbed dose rate in a cell under a constant neutron flux Jn reads, D˙(t) =
EtN˙(t)/Mcell, where N˙(t) = N0 exp (−t/τn) /τn is the number of the neutron capture reac-
tions in the cell per second, N0 is the initial (at t = 0) number of nuclide particles per cell;
τn = 1/(σnJn) is the reaction time constant; σn is the neutron capture cross section. For typ-
ical values of σn (see, Table I) and of the neutron flux, Jn < 10
13s−1cm−2, the reaction time
constant (τn > 10
6 s) is much larger than the reasonable duration of the NCT procedure (up
to few hours). Therefore, if N0 is not changing significantly during the neutron irradiation
procedure due to the accumulation and the excretion, the dose rate is time independent, and
the absorbed dose for time t of the neutron exposure reads, D(t) = tEtN0σnJn/Mcell. Then,
the number of nuclides per cell to have the absorbed dose D while exposing for time t to
neutron flux Jn, reads, Ncell = Nr/(tσnJn). The corresponding required mass concentration
of the nuclide, c ≡ M(nuclide)/Mcell, reads, c = Dµ/(EtNAσnJnt), where µ is the molar
mass of the nuclide and NA is the Avogadro constant. In Table II, we show the estimated
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concentration of nuclide (both Ncell and c) required to obtain the absorbed radiation dose of
D = 20 Gy in water after 1 hour exposition to Jn = 10
10 s−1cm−2 neutron flux for thermal
and epithermal neutron energies.
Once the neutrons enter the target (a water phantom or a human body) with initial
energy E0n, they start to scatter on the atoms (mainly elastically and on hydrogens) and to
slow down. The average neutron energy in the target, En(x), decreases with the depth x
from the initial energy En(0) at x = 0 till the thermal energy 3/2kBT at a given temperature
T , and the neutron capture cross section, σn(En(x)), for the active nuclide increase with x
reaching the value for the thermal neutrons. Besides, neutrons change their direction after
each collision, so that the initially collimated beam will disperse with the distance traveled in
the target. Therefore, the neutron flux Jn(x) along the initial beam direction decreases with
the depth x. As the absorbed dose is proportional to the product, D(x) ∝ σn(En(x))Jn(x),
it also depends on the depth x even at the uniform concentration of the active nuclide. If
the incident neutrons are already thermalized, their average energy and the capture cross
section are constant, so that the dose decreases with the depth due to the decrease of the
average flux. If the initial neutrons have a higher energy (0.5 eV-10 keV), the absorbed dose,
D(x), first increases with x together with the neutron capture cross section, then reaches
its maximum at a certain distance x0 (1-4 cm) [35], and then decreases due to the flux
angular dispersion. The interval of the depth, [xmin, xmax] around x0, where the absorbed
dose is higher than a certain critical value (e.g., 20 Gy/h) at a given nuclide concentration is
suitable for the NCT. For the 7Be and the 22Na nuclides, having the neutron capture cross
section larger than that for 10B by a factor of 10, the maximum working depth, xmax, can be
much larger than x0 and can reach 10-20 cm required for potential therapy of deep sitting
tumors.
c. The absorbed dose from the spontaneous radiation. To estimate the effects of the
spontaneous radiation of the 7Be and the 22Na nuclides, both for the patient and for the
personnel, we compare them with the iodine radioisotope, 131I, which emits similar radiation
and also is widely used in the therapy of thyroid cancer [41], see Table III. There are several
standard physical characteristics of the spontaneous decay. The iodine isotope has the
shortest lifetime, T1/2, of 8 days, while the sodium isotope’s half-life is the longest among
the three nuclides and equals 2.6 years. The activity of a radionuclide (the number of decays
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Table III. Comparison of the radiation effects of the spontaneous decay
Nuclide (half-life)
131I (8.0 d) 7Be (53 d) 22Na (2.60 y)
Mass-specific activity, Am [GBq/µg]
radiation type, its energy and the abundance
4.6 13 0.23
γ, 370 keV - average γ, 478 keV, f=0.10 γ, 1280 keV, f=1
β−, 570 keV - average β+, 540 keV , f=0.9
γ, 511 keV , f=1.8
Gamma constant at 1 m distance, Γ [mGy/h/GBq]
0.05 0.007 0.30
External absorbed dose rate, D˙ext, [mGy/h]
per 1 µg of nuclide at 1 m distance
0.23 0.09 0.07
Internal absorbed dose rate per 1 µg of nuclide, D˙int, [mGy/h]
contribution for each radiation type is specified separately
60 - γ 25 - γ 18 - γ
360 - β 15 - β
Total: 420 Total: 33
per second) of initial mass M , after time t reads,
A(t) = AmM exp
(
− ln(2) t
T1/2
)
,
where Am = ln(2)NA/(µT1/2) is the nuclide-mass-specific activity, µ is the molar mass.
Table III shows that the mass-specific activity for the 7Be is the largest despite the half-life
for 131I is shorter; apparently, it is due to the almost 20 times larger isotope mass for the
iodine.
To characterize the external (personnel and environmental) radiation risk of a radionu-
clide, one ordinary calculates the absorbed radiation dose rate at a certain distance d from a
point-like source of activity A. The distance is typically large enough (e.g., 1 m) so that all
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the β radiation is absorbed well before d, and only γ-radiation contributes to the ionization.
The external γ-radiation dose rate reads,
dDext
dt
= Γ A
d2
Ps.
Here, the gamma constant,
Γ =
1
4pi
µen
ρ
∑
i
Eiγf
i,
is a standard characteristics of the external radiation risk of the nuclide at given activity.
The sum in the latter equation runs over the energies of all the emitted gammas weighted by
the corresponding abundance (f i is the average number photons of type i per decay of the
nuclide). The energy attenuation coefficient, µen, determines the average relative energy loss
of the photon beam after passing distance x in the material E/E0 = exp(−µenx). As µen
is approximately proportional to the mass density, ρ, of the material, one often introduces
the mass-energy attenuation coefficient, µen/ρ. In particular, for both air and liquid water,
µen/ρ ≈ 0.03 cm2g−1 with the 20% accuracy for the photon energies from 60 keV to 2
MeV, [48]. The gamma shielding factor, Ps, describes reduction of the average energy of
the emitted photons due to the absorption and the inelastic scattering on the way from the
source to the observation point at the distance d. If the energy attenuation coefficient of the
shielding material, as it was discussed above in the text, µsen, weakly depends on the photon
energy, the shielding factor can be estimated as follows, Ps = exp (−µsenL), where L ≤ d is
thickness of the shield. In air, ρs = 0.001225 g cm
−3, the characteristic energy attenuation
length, λ = 1/µsen is about 270 m, so that at the distance below d=1 m, the shielding factor,
Ps = exp(−d/λ) ≈ 1. The energies and the corresponding abundances of the radiation are
shown in Table III. For 131I, more than 10 different photons may be emitted [49], we show only
the average (weighted) value,
∑
iE
i
γf
i, in the table. The calculated Γ constants reported in
Table III agree with the values recommended in [49] within 20% accuracy sufficient for the
nuclide comparison presented here. This also justifies the approximations accepted for the
simplified estimates of the absorbed doses. The calculated external dose rate at 1 m per 1
µg of nuclide, D˙ext, is reported in Table III.
To quantify the possible effect of the spontaneous radiation on the patient, we calculate
the average absorbed dose rate within a sphere of water of radius R = 10 cm around a point-
like source. The β-radiation from the spontaneous decay is completely absorbed within less
20
than 2 mm from the source [31] releasing the energy,
∑
iE
i
βf
i
β. The photons on average
loose only a part of their initial energy equal to (1 − exp(−µenR))
∑
iE
i
γf
i. The internal
absorbed dose rate is the sum of the two contributions, D˙int = D˙
γ
int + D˙
β
int,
dDγint
dt
= A (1− exp (−µenR))
∑
i
Eiγf
i 3
4piR3ρ
.
dDβint
dt
= A
∑
i
Eiβf
i
β
3
4piR3ρ
.
The calculated external dose rate per 1 µg of nuclide, D˙int, is reported in Table III for the
photons and the β-particles, separately.
The half-life, the mass-specific activity and the Γ constant reflects different physical
properties of radioactive nuclides, and, separately, are not sufficient to characterize the risk
of the spontaneous radiation. The mass-specific internal, D˙int, and external, D˙ext, dose rates
defined here are more suitable to compare radionuclides.
For the radiation therapy of thyroid cancer one uses the amount of 131I equivalent to the
activity ranging from 0.2 to more than 50 GBq [41]. As 4.6 GBq corresponds to 1 µg (see
Table III) of the nuclide, we can take 1 µg as a typical mass per procedure with 131I. The
same mass of 7Be in the target would be necessary to produce 20 Gy per hour in 1 g of tumor
in BeNCT (see, Table II). The external dose rate at 1 m, D˙ext, characterizing the radiation
risk for the environment and the personnel, is 2.5 time smaller for 7Be (0.09 mGy/h) than
for the typical therapeutic amount of 131I. For 22Na, the necessary mass of the nuclide is 3
µg per 1 g of tumor, and D˙ext = 0.21 mGy/h is similar to that of 1 µg of
131I.
The β component of the internal spontaneous dose is absorbed locally. It produces the
therapeutic effect in the tumor and it is harmful when the radionuclide is the healthy tissues.
In the case of 131I, the dose rate is D˙βint = 360 mGy/h for 1 µg of the nuclide. It is 8 times
lower for 3 µg of 22Na and it is absent for 7Be. However, the therapeutic effect of 22Na and
7Be comes from the neutron capture reaction and has the absorbed dose rate of 20 Gy/h,
i.e., it is more than 50 time stronger than for 131I.
The γ component of the internal dose is absorbed (by definition) within the sphere of
R = 10 cm from the decaying nuclides, and most probably, outside the tumor. Therefore,
it makes the radiation damage to healthy tissues with the same dose rate of about D˙γint =
60 mGy/h per 1 µg of 131I or per 3 µg of 22Na; the effect is 2.5 time smaller for 1 µg of 7Be.
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